TABLE 3.
Comparison of Characteristics of ACLF-3 patients, Grouped According to Survival, Transplantation, or Mortality Within 14 Days of Listing
| Survived without transplantation (n = 1,334) |
Transplanted (n = 2,349) |
Died or removed (n = 1,416) |
P | |
|---|---|---|---|---|
| Age, mean (SD) | 50.8 (11.1) | 51.2 (10.5) | 53.4 (10.2) | <0.001 |
| Male, n (%) | 813 (60.9) | 1,484 (63.2) | 852 (60.2) | 0.143 |
| Race, n (%) | 0.225 | |||
| Caucasian | 882 (66.1 | 1,488 (63.4) | 919 (64.9) | |
| African American | 157 (11.8) | 315 (13.4) | 174 (12.3) | |
| Hispanic | 216 (16.2) | 390 (16.6) | 221 (15.6) | |
| MELD score, median (IQR) | 36.5 (30.7–41.8) | 39.6 (35.2–43.4) | 41.0 (36.2–44.9) | <0.001 |
| MELD-Na score, median (IQR) | 36.9 (31.8–41.5) | 40 (35.8–42.7) | 40.8 (36.6–44) | 0.001 |
| Diabetes, n (%) | 290 (22.5) | 503 (22.0) | 320 (23.8) | 0.471 |
| Body mass index (median, IQR) | 27.9 (24.3–32.9) | 28.6 (24.9–33.1) | 28.7 (24.9–33.5) | 0.574 |
| Portal vein thrombosis, n (%) | 77 (6.2) | 141 (6.3) | 64 (4.9) | 0.208 |
| Etiology, n (%) | ||||
| NASH | 181 (13.7) | 304 (12.8) | 205 (14.5) | 0.410 |
| HCV | 405 (30.4) | 824 (35.1) | 505 (35.7) | 0.004 |
| ALD | 323 (24.0) | 581 (24.7) | 285 (20.1) | 0.004 |
| Liver failure, n (%) | 970 (72.8) | 1,968 (83.9) | 1,172 (82.8) | <0.001 |
| Mechanical ventilation, n (%) | 620 (46.5) | 829 (35.3) | 708 (50.0) | <0.001 |
| Circulatory failure, n (%) | 677 (50.8) | 937 (39.9) | 758 (53.5) | <0.001 |
| Coagulation failure, n (%) | 691 (51.8) | 1,574 (67.0) | 947 (66.9) | <0.001 |
| Neurologic failure, n (%) | 728 (54.6) | 1,194 (50.8) | 772 (54.5) | 0.030 |
| Renal failure, n (%) | 1,014 (76.0) | 1,891 (80.5) | 1,173 (82.8) | <0.001 |
| Organ failures | ||||
| Four | 396 (27.7) | 653 (27.8) | 599 (42.3) | <0.001 |
| Five | 140 (10.5) | 274 (11.6) | 271 (19.1) | <0.001 |
| Six | 32 (2.3) | 81 (3.5) | 113 (7.9) | <0.001 |